The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Autor: Frederik Barkhof, Richard Dobson, Sebastiaan Engelborghs, Kristel Sleegers, Julius Popp, Anders Wallin, Rik Vandenberghe, Simon Lovestone, Giovanni B. Frisoni, Alberto Lleó, Lars Bertram, Alison L. Baird, Philip Scheltens, Cristina Legido-Quigley, Mara ten Kate, Pieter Jelle Visser, Pablo Martinez-Lage, Stephanie J.B. Vos, Christine Van Broeckhoven, José Luis Molinuevo, Henrik Zetterberg, Johannes Streffer, Isabelle Bos
Přispěvatelé: RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, Promovendi MHN, Clinical sciences, Neurology, Pathologic Biochemistry and Physiology, Amsterdam Neuroscience - Neurodegeneration, Radiology and nuclear medicine
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Oncology
Research design
Proteomics
MILD COGNITIVE IMPAIRMENT
Biomedical Research
Neurology
Neuropsychological Tests
lcsh:RC346-429
Cohort Studies
ddc:616.89
Plasma
BLOOD-BASED BIOMARKERS
0302 clinical medicine
Neurofilament Proteins
Biomarker discovery
10. No inequality
Aged
80 and over
Genomics
Magnetic resonance imaging
Medicine(all)
medicine.diagnostic_test
DEMENTIA
Middle Aged
Alzheimer's disease
CEREBROSPINAL-FLUID BIOMARKERS
3. Good health
ALZHEIMERS-DISEASE
Cerebrospinal fluid
Research Design
Cohort
Female
Life Sciences & Biomedicine
Alzheimer’s disease
Cohort study
MRI
medicine.medical_specialty
Cognitive Neuroscience
Clinical Neurology
CSF BIOMARKERS
DIAGNOSIS
ATROPHY
lcsh:RC321-571
03 medical and health sciences
Alzheimer Disease
Internal medicine
medicine
Humans
Dementia
Metabolomics
Cognitive Dysfunction
Chitinase-3-Like Protein 1
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
Biology
lcsh:Neurology. Diseases of the nervous system
Aged
Alzheimer Disease/blood
Alzheimer Disease/diagnosis
Amyloid beta-Peptides/blood
Biomarkers/blood
Biomedical Research/methods
Chitinase-3-Like Protein 1/blood
Magnetic Resonance Imaging
Neurofilament Proteins/blood
Neurogranin/blood
Psychiatric Status Rating Scales
Biomarkers
DNA
Multimodal
Amyloid beta-Peptides
Science & Technology
Mini–Mental State Examination
business.industry
Research
Neurosciences
medicine.disease
030104 developmental biology
Neurogranin
Neurosciences & Neurology
Neurology (clinical)
Human medicine
business
030217 neurology & neurosurgery
Zdroj: Alzheimer's research & therapy
Alzheimer's Research & Therapy
Alzheimers Research & Therapy
Alzheimer's Research & Therapy, 10:64. BioMed Central Ltd
Alzheimer's Research and Therapy, Vol. 10, No 1 (2018) P. 64
Bos, I, Vos, S, Vandenberghe, R, Scheltens, P, Engelborghs, S, Frisoni, G, Molinuevo, J L, Wallin, A, Lleó, A, Popp, J, Martinez-Lage, P, Baird, A, Dobson, R, Legido-Quigley, C, Sleegers, K, Van Broeckhoven, C, Bertram, L, Ten Kate, M, Barkhof, F, Zetterberg, H, Lovestone, S, Streffer, J & Visser, P J 2018, ' The EMIF-AD Multimodal Biomarker Discovery study : design, methods and cohort characteristics ', Alzheimer's Research & Therapy, vol. 10, no. 1, pp. 64 . https://doi.org/10.1186/s13195-018-0396-5
Alzheimer's Research & Therapy, 10(1). BioMed Central
Alzheimer's research & therapy, vol. 10, no. 1, pp. 64
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-9 (2018)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 1758-9193
DOI: 10.1186/s13195-018-0396-5
Popis: Background There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. In this report we describe the design of the study, the methods used and the characteristics of the participants. Methods Participants were selected from existing prospective multicenter and single-center European studies. Inclusion criteria were having normal cognition (NC) or a diagnosis of mild cognitive impairment (MCI) or AD-type dementia at baseline, age above 50 years, known amyloid-beta (Aβ) status, availability of cognitive test results and at least two of the following materials: plasma, DNA, magnetic resonance imaging (MRI) or cerebrospinal fluid (CSF). Targeted and untargeted metabolomic and proteomic analyses were performed in plasma, and targeted and untargeted proteomics were performed in CSF. Genome-wide SNP genotyping, next-generation sequencing and methylation profiling were conducted in DNA. Visual rating and volumetric measures were assessed on MRI. Baseline characteristics were analyzed using ANOVA or chi-square, rate of decline analyzed by linear mixed modeling. Results We included 1221 individuals (NC n = 492, MCI n = 527, AD-type dementia n = 202) with a mean age of 67.9 (SD 8.3) years. The percentage Aβ+ was 26% in the NC, 58% in the MCI, and 87% in the AD-type dementia groups. Plasma samples were available for 1189 (97%) subjects, DNA samples for 929 (76%) subjects, MRI scans for 862 (71%) subjects and CSF samples for 767 (63%) subjects. For 759 (62%) individuals, clinical follow-up data were available. In each diagnostic group, the APOE ε4 allele was more frequent amongst Aβ+ individuals (p
Databáze: OpenAIRE
Externí odkaz: